A balloon angioplasty device that sucks up dangerous plaque debris could trigger a “paradigm shift” in how physicians treat peripheral artery disease, researchers write in the current issue of Endovascular Today.
“We will see a shift in how we tre…
Researchers from the Congenital Cardiovascular Interventional Study Consortium (CCISC) who evaluated the intermediate and long-term results of stent implantation for aortic coarctation found that cumulative intermediate success was 86%, and cumulati…
Patients with acute coronary syndromes initially treated with the anticoagulant fondaparinux who underwent a coronary procedure (such as balloon angioplasty) and received a lower dose of the anticoagulant heparin during the procedure did not have a …
FAIRFAX, Va. — Recognizing that venous interventions may potentially play an important role in treating some patients who suffer from multiple sclerosis — an incurable, disabling disease — the Society of Interventional Radiology has issued a posi…
Researchers at the Maine Medical Center Research Institute (MMCRI) in Scarborough, Maine, announce their discovery that the renarrowing of arteries following balloon angioplasty can be halted by copper chelation therapy. Preventing the function of copper in the body stops arteries from reclogging following the mechanical stress of removing arterial obstructions through angioplasty. The therapy works by limiting the cellular export of growth factors and cytokines involved in this process.
Taking cholesterol-lowering drugs before undergoing artery-clearing procedures appears to reduce deaths, heart attacks, and recurrent blockages among patients with elevated levels of an inflammation marker, according to research reported in today’s rapid access issue of Circulation: Journal of the American Heart Association. Previous studies have suggested that taking a class of cholesterol-lowering drugs called statins after percutaneous coronary interventions (PCI) such as balloon angioplasty or stenting could lower deaths.
A novel approach to treating high-risk stroke patients who were poor candidates for traditional clot-busting therapy enabled one-third of patients in a prospective trial, all of whom otherwise would be expected to suffer severe deficits, to return to functional independence, neurosurgeons at the University at Buffalo report.